^
Association details:
| Biomarker: | ARID1A mutation |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug Class: | PD1 inhibitor + Angiogenesis inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody
Published date:
07/07/2022
Excerpt:
Baseline clinical data, blood samples, and imaging data of the first evaluation after two cycles of treatment were collected for 40 patients with advanced HCC...The high mutation frequency of TP53 and ARID1A appeared in the non-response cohort.
DOI:
10.3389/fimmu.2022.930096
